Acquires, develops and commercialises late‑stage and established rare‑disease medicines to improve outcomes for patients with high unmet need. Operates a scalable, best‑in‑class rare‑disease commercialisation platform with late‑stage development and licensing expertise, offering flexible, transparent in‑licensing and acquisition partnerships.